Adjuvant Therapy for Breast Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Adjuvant Therapy for Breast Cancer PDF full book. Access full book title Adjuvant Therapy for Breast Cancer by Monica Castiglione. Download full books in PDF and EPUB format.
Author: Monica Castiglione
Publisher: Springer Science & Business Media
ISBN: 0387751157
Category : Medical
Languages : en
Pages : 483
Get Book Here
Book Description
Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
Author: Monica Castiglione
Publisher: Springer Science & Business Media
ISBN: 0387751157
Category : Medical
Languages : en
Pages : 483
Get Book Here
Book Description
Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
Author: Georges Mathe;&AAe;
Publisher: Springer Science & Business Media
ISBN: 3642816851
Category : Medical
Languages : en
Pages : 404
Get Book Here
Book Description
Transplantation of syngeneic (donor is a monozygous twin) or allogeneic (donor is an HLA-identical sibling) marrow provides the opportunity for aggressive antileukemic therapy without regard to marrow toxicity. Until 1975, marrow transplantation was carried out only after failure of all other therapy. Consequently, most patients were in advanced relapse. Six of 16 recipients of syngeneic marrow and 13 of 100 recipients of allogeneic marrow are still in remission after 5. 5-10 years [3, 7]. An actuarial survival curve of the first 100 patients grafted in Seattle after conditioning with cyclophos phamide (60 mg/kg on each of 2 successive days) and total body irradiation (1,000 rad) showed three periods of interest: (1) The first 4 months showed a rapid loss of patients associated with advanced illness, graft-versus-host disease, infections (in particular interstitial pneumonias), and recurrent leukemia; (2) from 4 months to 2 years, the curve showed a much slower rate of decline attributable primarily to recurrent leukemia; and (3) from 2-10 years, the curve was almost flat with a negligible loss of patients and no recurrent leukemia. This flat portion of the curve corresponded to 13% of the patients and indicates a strong probability that the majority of these survivors are cured of their disease [8]. Attempts at reducing the incidence of leukemic relapse after transplantation were made by a number of marrow transplant groups by added chemotherapy.
Author: Gianni Bonadonna
Publisher: Springer Science & Business Media
ISBN: 3642813321
Category : Medical
Languages : en
Pages : 479
Get Book Here
Book Description
1978 Annual Plenary Meeting of the European Organization for Research on Treatment of Cancer, Paris, June 1978
Author: I. Craig Henderson
Publisher: Springer Science & Business Media
ISBN: 1461534968
Category : Medical
Languages : en
Pages : 462
Get Book Here
Book Description
The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer. Many of the tumors that we have been most successful in curing with chemotherapy and other newer forms of treatment are relatively uncommon. In contrast, breast cancer continues to be the single most common malignancy among women in the western world, is increasingly a cause of death throughout Asia and Third-World countries, and remains one of the most substantial causes of cancer mortality world wide. The use of mammography as a means of early detection has been shown to reduce breast cancer mortality by 25-35% among those popu lations in which it is utilized. The use of adjuvant systemic treatment in appropriate patients provides a similar (and additional) reduction in breast cancer mortality. Few subjects have been so systematically studied in the history of medicine, and it seems fair to conclude that the value to adjuvant systemic therapy in prolonging the lives of women with breast cancer is more firmly supported by empirical evidence than even the more conventional or primary treatments using various combinations ofsurgery and radiotherapy.
Author: I. Craig Henderson
Publisher: Springer
ISBN: 9781461365501
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer. Many of the tumors that we have been most successful in curing with chemotherapy and other newer forms of treatment are relatively uncommon. In contrast, breast cancer continues to be the single most common malignancy among women in the western world, is increasingly a cause of death throughout Asia and Third-World countries, and remains one of the most substantial causes of cancer mortality world wide. The use of mammography as a means of early detection has been shown to reduce breast cancer mortality by 25-35% among those popu lations in which it is utilized. The use of adjuvant systemic treatment in appropriate patients provides a similar (and additional) reduction in breast cancer mortality. Few subjects have been so systematically studied in the history of medicine, and it seems fair to conclude that the value to adjuvant systemic therapy in prolonging the lives of women with breast cancer is more firmly supported by empirical evidence than even the more conventional or primary treatments using various combinations ofsurgery and radiotherapy.
Author: Desmond C. Winter
Publisher: John Wiley & Sons
ISBN: 1119518407
Category : Medical
Languages : en
Pages : 324
Get Book Here
Book Description
An innovative guide to the practice of pelvic exenterative surgery for the management of advanced pelvic neoplasms Exenterative surgery plays an important role in the management of advanced pelvic cancer. However, while a large body of evidence regarding outcomes following pelvic exenteration now exists, practical strategies and management options remain unclear. Surgical Management of Advanced Pelvic Cancer addresses this problem by assembling world-leaders in the field to provide insights into the latest techniques and best practices. It includes detailed coverage of: Surgical anatomy Operative approaches and exenterative techniques Reconstruction options Current evidence on survival and quality of life outcomes Featuring essential information for those managing patients with advanced pelvic neoplasms, Surgical Management of Advanced Pelvic Cancer consolidates the latest data and practical advice in one indispensable guide.
Author: Sydney E. Salmon
Publisher: Lippincott Williams & Wilkins
ISBN: 9780397584437
Category : Medical
Languages : en
Pages : 330
Get Book Here
Book Description
Author: Gianni Bonadonna
Publisher: Springer Science & Business Media
ISBN: 3642813208
Category : Medical
Languages : en
Pages : 263
Get Book Here
Book Description
P. Denoix and G. Mathe Approximately 70% of cancer patients relapse after surgery before the 5th year and, in most cases, for example in breast carcinoma, they relapse still later up to the 20th year. For some considerable time, the strategy of cancer treatment has been limited to the sophistication of surgery-radiotherapy combinations that maximally decreased the incidence of local and regional relapses in sites that were within their reach. Today, the practice of clinical oncology is unthinkable without the active participation of the medical oncologist. He is the "third man" of the clinical oncology team, and he has recently focused attention on the fact that most relapses arise from distant metastases due to the proliferation of cells seeded there after having left the primary tumor site at the time of operation and, hence, are inaccessible to any form oflocal and/or regional treatment. On this evidence, medical oncologists have proposed the application of medical treatments for disseminated minimal residual disease (MRD). They have two available means: chemother apy and immunotherapy. Medical oncologists in general can be divided into three groups: chemotherapists, immunotherapists, and chemoimmunotherapists. The pure chemotherapists, who had already cured some malignant neoplasias such as Hodgkin's disease, acute lymphoid leukemia, placental choriocarcinoma, and Wilms' tumor, thought they might have the means of attacking the residual disease of common cancers.
Author:
Publisher:
ISBN:
Category : Breast
Languages : en
Pages : 16
Get Book Here
Book Description
Author: Faruque Riffat
Publisher: Springer
ISBN: 8132224973
Category : Medical
Languages : en
Pages : 214
Get Book Here
Book Description
Non-melanoma skin cancer is a global public health issue. With an ever-increasing, and ageing, world population coupled with increasing numbers of immunosuppressed individuals the number of patients continues to rise. The head and neck is overwhelmingly the most frequent location for the development of a non-melanoma skin cancer and as such challenges the clinician with its complex anatomy. The importance of maintaining the aesthetics of the face and the function of the anatomy cannot be overstated, yet ultimately it is always the aim of curing a patient with the minimum of morbidity that clinicians strive for. However, the spectrum of presentations and subsequent management varies widely, ranging from patients with the ubiquitous low-risk mid-face basal cell carcinoma to those diagnosed with relatively uncommon but potentially life-threatening high-risk squamous cell carcinomas (e.g. involving metastatic lymph nodes or with perineural invasion present) and Merkel cell carcinomas.
